1. >
  2. Investors
  3. >
  4. Regulated Information
  5. >
  6. Press Releases – Reg...

PRESS RELEASES

Found 289 Results
Page 27 of 29

BioAlliance Pharma and Topotarget enter into merger agreement to create a leading orphan oncology company


— Combined company expected to have increased scale and a highly complementary pipeline of late-stage products addressing significant unmet medical […]

Tags:

04/16/2014


BioAlliance Pharma announces a new positive DSMB recommendation to continue its Phase III clinical trial with Livatag® in primary liver cancer


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

04/14/2014


Publication of the 2013 Registration Document


BioAlliance Pharma SA (Euronext Paris – BIO), Société d’innovation spécialisée dans le développement de médicaments visant des pathologies orphelines en […]

Tags:

04/08/2014


BioAlliance Pharma Announces Shareholders’ Meeting and Approval of all resolutions


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Tags:


BioAlliance Pharma signs a new licensing agreement with Daewoong Pharmaceutical Co., Ltd. for Sitavig®’s commercialization in South Korea


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Tags:

04/02/2014


BioAlliance Pharma provides an update on its partnerships for Loramyc®/Oravig®


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Tags:

04/01/2014


BioAlliance Pharma collaborates with Penn Pharma on the industrial development of Validive®


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

03/31/2014


Sitavig® Licensing Strategy: Execution of licensing agreement with Innocutis for North America and Positive opinion from French and German Health Authorities for Marketing Authorization


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced major […]

03/19/2014


BioAlliance Pharma provides updates on its major achievements and reports 2013 consolidated financial results


2013: Significant progress on key strategic programs • Livatag® phase III (ReLive): European expansion and authorization from the FDA to […]

Tags:

02/27/2014


Strengthening and extension of the industrial protection of Livatag® until 2031 – First delivery of a new European patent


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced today […]

02/18/2014


Page 27 of 29